J Korean Ophthalmol Soc.  2021 Apr;62(4):496-506. 10.3341/jkos.2021.62.4.496.

Early Retinal Hemorrhage Absorption Rate and Long Term Clinical Outcomes in Branch Retinal Vein Occlusion

Affiliations
  • 1Department of Ophthalmology, Dankook University College of Medcine, Cheonan, Korea
  • 2Jincheon Health Center, Jincheon, Korea
  • 3Department of Ophthalmology, Chuncheon Sacred Heart Hospital, Hallym University College of Medicine, Chuncheon, Korea
  • 4Sanbon Samsung Eyeclinic, Gunpo, Korea

Abstract

Purpose
We report the relationship between early retinal hemorrhage absorption rate (RHAR) and long-term clinical outcomes associated with branch retinal vein occlusion (BRVO).
Methods
This retrospective study included 66 eyes with BRVO. We used a grid as a quantitative measurement unit for measuring the amount of hemorrhage, and calculated the RHAR by measuring variance between sums of the grids. We investigated the relationship of best corrected visual acuity (BCVA), central foveal thickness (CFT), and other long term clinical outcomes with RHAR.
Results
The RHAR in BRVO patients measured 16.46 ± 21.48 ∑grid/time (month). Improvement of BCVA (logMAR) was 0.28 ± 0.28 at 12 months, showing statistical significance with the RHAR (p < 0.01). We divided RHAR into two groups by 7.5 ∑ grid/month; slow and fast RHAR groups. Improvement of BCVA (logMAR) was 0.16 ± 0.23 in the slow RHAR group, and 0.38 ± 0.28 in the fast RHAR group, with statistical significance (p = 0.01). Regression of CFT was 133.12 ± 142.93 μm in the slow RHAR group, and 236.62 ± 131.55 μm in the fast RHAR group, with statistical significance (p < 0.01).
Conclusions
RHAR may be a prognostic factor during follow-up in BRVO patients.

Keyword

Best corrected visual acuity; Branch retinal vein occlusion; Central foveal thickness; Grid; Retinal hemorrhage absorbing rate
Full Text Links
  • JKOS
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr